Cart
sales@molnova.com
Aristolochic acid C
CAS No. 4849-90-5
Aristolochic acid C( 10-Hydroxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid )
Catalog No. M29048 CAS No. 4849-90-5
Aristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 102 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAristolochic acid C
-
NoteResearch use only, not for human use.
-
Brief DescriptionAristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.
-
DescriptionAristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms10-Hydroxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4849-90-5
-
Formula Weight327.248
-
Molecular FormulaC16H9NO7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (381.97 mM)
-
SMILESOC(=O)c1cc2OCOc2c2c3cc(O)ccc3cc([N+]([O-])=O)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SB-674042
SB-674042 is a potent, selective dual antagonist of the non-peptide orexigenic peptides OX1 and OX2 receptors, with IC50 values of 3.76 nM and 531 nM, respectively.
-
Ornidazole
Ornidazole(Ro 7-0207) is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria.
-
MAGE-A3 195-203
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.
